Anticoagulation Duration for Deep Vein Thrombosis

Initial Treatment and Duration

The American College of Chest Physicians recommends that all patients with DVT receive at least 3 months of therapeutic anticoagulation to prevent thrombus extension and early recurrence, regardless of DVT type 1, 2
Target INR of 2.5 (range 2.0-3.0) should be maintained for warfarin therapy, or use therapeutic-dose DOACs 1

For surgery-provoked DVT, annual recurrence risk is <1% after completing 3 months of treatment, and anticoagulation beyond 3 months is not routinely required 1
For hormone-associated DVT in women, stop anticoagulation at 3 months if hormonal therapy is discontinued, as these patients have approximately 50% lower recurrence risk compared to unprovoked VTE 1, 2
For unprovoked proximal DVT, annual recurrence risk exceeds 5% after stopping anticoagulation, and anticoagulation should be considered indefinitely as long as bleeding risk is not prohibitively high 1, 2

Low bleeding risk factors that favor indefinite therapy include age <70 years, no previous major bleeding episodes, no concomitant antiplatelet therapy, no renal or hepatic impairment, and good medication adherence 2, 4
High bleeding risk factors that favor stopping at 3 months include age ≥80 years, previous major bleeding, recurrent falls, need for dual antiplatelet therapy, and severe renal or hepatic impairment 2, 4

For extended therapy, consider reduced-dose DOACs, such as apixaban 2.5 mg twice daily, which may be used for extended-phase anticoagulation (weak recommendation) 4
Indefinite anticoagulation is strongly recommended for recurrent unprovoked DVT, with annual recurrence risk exceeding 10-15% if anticoagulation is stopped 4